Is Adolescent-Onset First-Episode Psychosis Different From Adult Onset? - 21/08/11
, Rahul Manchanda, FRCPC, Jatinder Takhar, FRCPC, Raj Haricharan, FRCPCABSTRACT |
Objective |
To examine whether first-episode psychosis patients with onset during adolescence (ages 15-18) differ significantly from those with young-adult onset (ages 19-30).
Method |
Consecutive patients presenting with first-episode psychosis (N = 242) were assessed for demographic and illness characteristics such as duration of untreated psychosis, diagnosis, length of prodromal period, premorbid adjustment, level of psychotic, negative, depressive, anxiety, and extrapyramidal symptoms, and alcohol and drug use.
Results |
Eighty-two patients (40.8%) had an onset of psychosis during adolescence (ages 15-18) and 119 (59.2%) during young adulthood (ages 19-30). The adolescent-onset group experienced longer delays in treatment of psychosis (duration of untreated psychosis) (p < .02), showed modestly worse premorbid functioning during late adolescence (p < .05), and were more likely to present with bizarre behavior (p < .01) and primary negative symptoms (p < .01).
Conclusions |
Patients with adolescent onset of psychosis are more likely to present with clinical characteristics that portend a poorer outcome and may require a different approach to early identification and treatment.
Le texte complet de cet article est disponible en PDF.Key Words : first-episode psychosis, adolescent vs. adult onset, schizophrenia
Plan
| The early intervention research project (PEPP), from which the data reported here were derived, was funded through an operating grant from the Canadian Institutes of Health Research. Assistance in preparation of the manuscript was generously provided by Marita Pruessner and Laura Béchard-Evans. Disclosure: Drs. Malla, Manchanda, Takhar, and Haricharan have acted in an advisory capacity, provided consultations on clinical research studies, or received honoraria from Janssen, Pfizer, Eli Lilly, and AstraZeneca. Dr. Malla has also received research funding from Janssen, Eli Lilly, and AstraZeneca. Dr. Ballageer has no financial relationships to disclose. |
Vol 44 - N° 8
P. 782-789 - août 2005 Retour au numéro
Article précédent
- Children With a Prepubertal and Early Adolescent Bipolar Disorder Phenotype From Pediatric Versus Psychiatric Facilities
- Rebecca Tillman, Barbara Geller, Jeanne Frazier, Linda Beringer, Betsy Zimerman, Tricia Klages, Kristine Bolhofner
- The Utility of Elementary School TOCA-R Scores in Identifying Later Criminal Court Violence Among Adolescent Females
- Hanno Petras, Nicholas Ialongo, Sharon F. Lambert, Sandra Barrueco, Cindy M. Schaeffer, Howard Chilcoat, Sheppard Kellam
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?